Frank Huygen

Prof. Dr. Frank Huygen


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2021 in Pain
Verified
Journal Article
Open access
AGAndreas Goebel
Andreas Goebel
FBFrank Birklein
Frank Birklein
FBFlorian Brunner
Florian Brunner
JCJ. David Clark
J. David Clark
JGJeanne Gierthmuehlen
Jeanne Gierthmuehlen
SBStephen Bruehl
Stephen Bruehl
An abstract is unavailable. This article is available as a PDF only.

30 November 2006 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
JGJ George Groeneweg
J George Groeneweg
FHFrank Huygen
Frank Huygen
CHClaudia Heijmans-Antonissen
Claudia Heijmans-Antonissen
SNSjoerd Niehof
Sjoerd Niehof
FZFreek J Zijlstra
Freek J Zijlstra
In complex regional pain syndrome type 1 (CRPS1) pro-inflammatory mediators and vascular changes play an important role in the sustained development and outcome of the disease. The aim of this study was to determine the involvement of vasoactive substances endothelin-1 (ET-1) and nitric oxide (NO) during early chronic CRPS1. Included were 29 patients with CRPS 1 who were diagnosed during the acute stage of their disease and observed during follow-up visits. Disease activity and impairment were determined and artificial suction blisters were made on the CRPS1 and the contralateral extremities for measurements of IL-6, TNF-α, ET-1 and nitrate/nitrite (NOx). The levels of IL-6, TNF-α and ET-1 in blister fluid in the CRPS1 extremity versus the contralateral extremity were significantly increased and correlated with each other, whereas NOx levels were decreased. The NOx/ET-1 ratio appears to be disturbed in the intermediate stage of CRPS, resulting in vasoconstriction and consequently in a diminished tissue blood distribution.

1 February 2004 in Immunology Letters
Verified
Journal Article
Closed access
FHFrank Huygen
Frank Huygen
NRNavin Ramdhani
Navin Ramdhani
ATAlbert van Toorenenbergen
Albert van Toorenenbergen
JKJan Klein
Jan Klein
FZFreek J. Zijlstra
Freek J. Zijlstra

6 December 2017 in Pain Practice
Verified
Journal Article
Closed access
PDF file
FHFrank Huygen
Frank Huygen
LLLiong Liem
Liong Liem
WCWilliam Cusack
William Cusack
JKJeffery Kramer
Jeffery Kramer

9 March 2021 in Pain
Verified
Journal Article
Open access
CGChristopher Gilligan
Christopher Gilligan
WVWillem Ffpmanzca Volschenk
Willem Ffpmanzca Volschenk
MRMarc Ffpmanzca Russo
Marc Ffpmanzca Russo
MGMatthew Green
Matthew Green
CGChristopher Gilmore
Christopher Gilmore
SESam S. Eldabe
Sam S. Eldabe
Chronic low back pain can be caused by impaired control and degeneration of the multifidus muscles and consequent functional instability of the lumbar spine. Available treatment options have limited effectiveness and prognosis is unfavorable. We conducted an international randomized, double-blind, sham-controlled trial at 26 multidisciplinary centers to determine safety and efficacy of an implantable, restorative neurostimulator designed to restore multifidus neuromuscular control and facilitate relief of symptoms (clinicaltrials.gov identifier: NCT02577354). Two hundred four eligible participants with refractory mechanical (musculoskeletal) chronic LBP and a positive prone instability test indicating impaired multifidus control were implanted and randomized to therapeutic (N = 102) or low-level sham (N = 102) stimulation of the medial branch of the dorsal ramus nerve (multifidus nerve supply) for 30 minutes twice daily. The primary endpoint was the comparison of responder proportions (≥30% relief on the LBP visual analogue scale without analgesics increase) at 120 days. After the primary endpoint assessment, participants in the sham-control group switched to therapeutic stimulation and the combined cohort was assessed through 1 year for long-term outcomes and adverse events. The primary endpoint was inconclusive in terms of treatment superiority (57.1% vs 46.6%; difference: 10.4%; 95% confidence interval, −3.3% to 24.1%, P = 0.138). Prespecified secondary outcomes and analyses were consistent with a modest but clinically meaningful treatment benefit at 120 days. Improvements from baseline, which continued to accrue in all outcome measures after conclusion of the double-blind phase, were clinically important at 1 year. The incidence of serious procedure- or device-related adverse events (3.9%) compared favorably with other neuromodulation therapies for chronic pain.

12 May 2006 in BioMedical Engineering OnLine
Verified
Journal Article
Open access
PDF file
SNSjoerd P Niehof
Sjoerd P Niehof
FHFrank Huygen
Frank Huygen
RWRick Wp van der Weerd
Rick Wp van der Weerd
MWMirjam Westra
Mirjam Westra
FZFreek J Zijlstra
Freek J Zijlstra
Complex Regional Pain Syndrome type 1 (CRPS1) is a clinical diagnosis based on criteria describing symptoms of the disease. The main aim of the present study was to compare the sensitivity and specificity of calculation methods used to assess thermographic images (infrared imaging) obtained during temperature provocation. The secondary objective was to obtain information about the involvement of the sympathetic system in CRPS1. We studied 12 patients in whom CRPS1 was diagnosed according to the criteria of Bruehl. High and low whole body cooling and warming induced and reduced sympathetic vasoconstrictor activity. The degree of vasoconstrictor activity in both hands was monitored using a videothermograph. The sensitivity and specificity of the calculation methods used to assess the thermographic images were calculated. The temperature difference between the hands in the CRPS patients increases significantly when the sympathetic system is provoked. At both the maximum and minimum vasoconstriction no significant differences were found in fingertip temperatures between both hands. The majority of CRPS1 patients do not show maximal obtainable temperature differences between the involved and contralateral extremity at room temperature (static measurement). During cold and warm temperature challenges this temperature difference increases significantly. As a result a higher sensitivity and specificity could be achieved in the diagnosis of CRPS1. These findings suggest that the sympathetic efferent system is involved in CRPS1.